TCR2 Therapeutics, a preclinical biotech developing immunotherapies for solid tumors and blood cancers, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
The Cambridge, MA-based company was founded in 2015 and plans to list on the Nasdaq under the symbol TCRR. TCR2 Therapeutics filed confidentially on September 7, 2018. Jefferies, Leerink Partners and BMO Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
